We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Factors Associated With Plasma IL-6 Levels During HIV Infection.
- Authors
von Stockenstrom, Susanne; Odevall, Lina; Eunok Lee; Sinclair, Elizabeth; Bacchetti, Peter; Killian, Maudi; Epling, Lorrie; Wei Shao; Rebecca Hoh; Terence Ho; Faria, Nuno R.; Lemey, Philippe; Albert, Jan; Hunt, Peter; Loeb, Lisa; Pilcher, Christopher; Poole, Lauren; Hatano, Hiroyu; Ma Somsouk; Douek, Daniel
- Abstract
Background. Elevated interleukin 6 (IL-6) levels have been linked to cardiovascular disease, cancer and death. Persons with human immunodeficiency virus (HIV) infection receiving treatment have higher IL-6 levels, but few data are available on factors associated with circulating IL-6. Methods. Participants in 3 trials with IL-6 measured at baseline were included (N = 9864). Factors associated with IL-6 were identified by linear regression. Demographic and HIV variables (nadir/entry CD4+ cell count, HIV RNA level, antiretroviral therapy regimen) were investigated in all 3 trials. In the SMART (Strategies for Management of Anti-Retroviral Therapy) trial, CD4/CD8 ratio, smoking, comorbid conditions, serum lipids, renal function (estimated glomerular filtration rate [eGFR]), and educational level were assessed. Results. Demographics associated with higher IL-6 levels were older age and lower education, whereas black race was associated with lower IL-6. Higher HIV RNA levels were associated with higher IL-6 levels, and higher nadir CD4+ cell counts with lower IL-6 levels. Compared with efavirenz, protease inhibitors were associated with higher and nevirapine with lower IL-6 levels. Smoking and all comorbid conditions were related to higher IL-6. IL-6 levels increased with decreasing eGFR and decreasing serum lipids. Conclusions. Higher levels of IL-6 were associated with older age, nonblack race, higher body mass index, lower serum lipid levels, HIV replication, low nadir CD4+ cell count, protease inhibitor use, comorbid conditions, and decreased eGFR. Multiple factors affect inflammation in HIV and should be considered in studies of IL-6 as a biomarker of clinical outcomes.
- Subjects
HIV infections; THERAPEUTICS; HIGHLY active antiretroviral therapy; CELL proliferation; DNA viruses; T cells; VIRAL genomes; PHYLOGENY
- Publication
Journal of Infectious Diseases, 2015, Vol 212, Issue 4, p585
- ISSN
0022-1899
- Publication type
Article
- DOI
10.1093/infdis/jiv123